EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network

☰ Menu

Núria Pascual

Name of the laboratory

08034 Barcelona, Spain
34 93 400 61 00

Members of the laboratory

Technical Director
Scientific Director

Laboratory activity

CAbS is a joint facility established under the umbrella of the Institute for Advanced Chemistry of Catalonia of the Spanish Council for Scientific Research (IQAC-CSIC) and the Networking Research Center for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). Our goal is to offer an integral service regarding production and use of monoclonal and polyclonal antibodies. Antibodies for proteins, peptides, small organic molecules or other antigens can be produced using standard or customized protocols according to the client’s needs. CAbS takes each customer's needs into consideration and discusses the most appropriate approach to accomplish their objectives.

CAbS is managed by the scientific team of the Nb4D group (Nb4D), recognized for their expertise in hapten synthesis, antibody production and immunochemical method development. Nb4D provides all the necessary advice and support to each project.

Research activities

The Nanobiotechnology for Diagnostics (Nb4D) Group has been involved in almost 40 projects including 8 European projects. Nb4D has collaborated with other CSIC (Spanish Scientific Council) groups, international research groups, universities, technological centres, small enterprises and large companies. The group also receives support from local and national governmental agencies.

Techniques available

Monoclonal Antibody Development

The standard service includes:

Customer delivery of cryo-stored clones on dry ice (3 vials for the 1-3 selected clones) and 10 ml of cell culture supernatant/cell line.

Polyclonal Antibody Development

The standard service includes:

The costumer will receive 50-80 mL of the final serum from each rabbit and about 5 mL samples of the pre-immune.

Additional services (optional):

Publications (2012-present)